Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,263.00+0.66%ETH$2,512.60+2.72%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CS

NASDAQ · CSTL

Castle Biosciences, Inc.

Healthcare · Medical - Diagnostics & Research

$32.32

Up+$0.01 (+0.03%)

Updated Sep 11, 2026, 10:54 PM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.11B
P/E ratio
-115.98
Dividend yield
0.00%
52-week range
$17.72 – $35.20
Volume
237.83K
Avg. volume
400.7K

Price performance

CSTL price history

1M range · 20 trading sessions · Daily adjusted prices

CSTL closed at $32.32 after 20 trading sessions, up 5.79% for the selected period.

Last close
$32.32
Period change
+5.79%
Period low
$29.03
Period high
$35.00
Daily close
View OHLC price history
CSTL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$31.97$32.70$31.44$32.32237.83K
Sep 9, 2026$32.43$33.03$32.00$32.31194.56K
Sep 8, 2026$32.57$33.58$32.28$32.76217.02K
Sep 4, 2026$32.32$33.21$31.985$32.91187.73K
Sep 3, 2026$33.50$34.00$32.38$32.65268.01K
Sep 2, 2026$33.36$34.73$32.69$33.42200.27K
Sep 1, 2026$33.00$34.09$32.89$33.44396.18K
Aug 31, 2026$33.03$33.295$32.36$33.03258.01K
Aug 28, 2026$34.02$34.275$32.80$33.50372.59K
Aug 27, 2026$34.01$34.89$33.982$34.26251.21K
Aug 26, 2026$34.80$34.84$33.62$34.08456.26K
Aug 25, 2026$33.47$35.20$33.29$35.00483.37K
Aug 24, 2026$33.65$34.54$31.695$33.47357.67K
Aug 21, 2026$32.85$34.70$32.14$34.20573.47K
Aug 20, 2026$32.41$34.01$32.41$32.93322.94K
Aug 19, 2026$29.03$32.39$29.03$32.32451.92K
Aug 18, 2026$29.89$30.125$28.72$29.03596.61K
Aug 17, 2026$29.50$30.50$29.21$29.95225.81K
Aug 14, 2026$30.93$31.115$29.58$29.62264.21K
Aug 13, 2026$31.62$31.97$30.51$30.55362.23K

Latest CSTL news

The latest Smart Investors Daily articles mentioning CSTL.

Stock researchCompany · Overview

CSTL research

Overview

Company profile and research snapshot.

Company profile

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$38.00
Implied upside
—
Analysts
—
CSTL recent ratings
DateFirmRatingTarget
Aug 3, 2026BTIGBuy—
Jun 25, 2026Roth CapitalBuy—
May 13, 2026BTIGBuy—
May 7, 2026BairdOutperform—
Apr 20, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Feb 19, 2026

Castle Biosciences Publishes A Prospective, Multicenter Clinical Validation Study In The Journal Of The American Academy Of Dermatology Demonstrating That Its AdvanceAD-Tx Test Can Identify Patients With Moderate-To-Severe Atopic Dermatitis Who Are More Likely To Achieve Greater And Faster Clinical Responses When Treated With A Janus Kinase Inhibitor Compared To T Helper Type 2 Targeted Therapies

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By